Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Clinical Immunology
Published in: Journal of Clinical Immunology 5/2008

01-09-2008

IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases

Authors: Stella Gabeta, Gary L. Norman, Nikolaos Gatselis, Christos Liaskos, Panagiotis A. Papamichalis, Athanasios Garagounis, Kalliopi Zachou, Eirini I. Rigopoulou, George N. Dalekos

Published in: Journal of Clinical Immunology | Issue 5/2008

Login to get access

Abstract

Introduction

Recently, we reported a high prevalence of immunoglobulin G and/or immunoglobulin M anticardiolipin antibodies (aCL) in patients with autoimmune liver diseases, namely, autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), which were independent of the respective isotypes of antibodies against β2-glycoprotein I (anti-b2GPI). Immunoglobulin A (IgA) aCL and IgA anti-b2GPI are the least studied of the three specific isotypes either in antiphospholipid syndrome (APS) or in other conditions.

Methods

Therefore, we investigated the prevalence and clinical significance of IgA anti-b2GPI and IgA aCL by enzyme-linked immunosorbent assays in another set of Caucasian patients with autoimmune liver diseases (59 AIH, 96 PBC, and 37 PSC). The disease controls group consisted of 50 hepatitis C virus (HCV) patients, 50 hepatitis B virus (HBV), 30 alcoholic liver disease (ALD), 30 non-alcoholic steatohepatitis (NASH), and 110 healthy controls.

Results and Discussion

IgA anti-b2GPI prevalence was higher in AIH (50.8%) compared to PBC (p = 0.005), PSC (p = 0.008), NASH (p = 0.004), ALD (p = 0.01), and HCV (p = 0.002). The titers were also significantly higher in AIH compared to any other group of the study. IgA aCL prevalence was higher in AIH (33.9%) compared to PBC (p = 0.005), PSC (p = 0.014), NASH (p = 0.001), ALD (p = 0.004), and HCV (p < 0.001). IgA anti-b2GPI or IgA aCL were not associated with APS features in patients with liver autoimmunity. Of note, IgA anti-b2GPI and IgA aCL were associated with clinical and biochemical markers of disease severity in AIH and PBC. We demonstrated a high prevalence and high titers of IgA anti-b2GPI in patients with AIH compared to any other liver disease of the study.

Conclusion

IgA anti-b2GPI and IgA aCL were associated with the severity and biochemical activity of AIH and PBC, but long-term prospective studies are needed to address whether this new finding is of clinical importance in AIH and PBC patients.
Literature
1.
Miyakis S, Locksin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.PubMedCrossRef
2.
Bas de Laat H, Derksen RH, de Groot PG. β2-Glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin Immunol 2004;112:161–8.PubMedCrossRef
3.
Atsumi T, Amengual O, Yasuda S, Matsuura E, Koike T. Research around beta2-glycoprotein I: a major target for antiphospholipid antibodies. Autoimmunity 2005;38:377–81.PubMedCrossRef
4.
Dalekos GN, Manoussakis MN, Goussia AC, Tsianos EV, Moutsopoulos HM. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis. Gut 1993;34:658–64.PubMedCrossRef
5.
Dalekos GN, Zachou K, Liaskos C. The antiphospholipid syndrome and infection. Curr Rheumatol Rep 2001;3:277–85.PubMedCrossRef
6.
Petrovas C, Vlachogiannopoulos PG, Kordossis T, Moutsopoulos HM. Anti-phospholipid antibodies in HIV infection and SLE with or without antiphospholipid syndrome: comparisons of phospholipids specificity, avidity and reactivity with beta2-GPI. J Autoimmun 1999;13:347–55.PubMedCrossRef
7.
Dalekos GN, Manoussakis MN, Zervou E, Tsianos EV, Moutsopoulos HM. Immunologic and viral markers in the circulation of anti-HIV negative heroin addicts. Eur J Clin Invest 1993;23:219–25.PubMedCrossRef
8.
Zachou K, Liaskos C, Christodoulou DK, Kardasi M, Papadamou G, Gatselis N, et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest 2003;33:161–8.PubMedCrossRef
9.
Dalekos GN, Kistis KG, Boumba DS, Voulgari P, Zervou EK, Drosos AA, et al. Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. Eur J Gastroenterol Hepatol 2000;12:67–74.PubMedCrossRef
10.
Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2000;109:797–804.
11.
Liaskos C, Rigopoulou E, Zachou K, Georgiadou S, Gatselis N, Papamihali R, et al. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun 2005;24:251–60.PubMedCrossRef
12.
Zachou K, Liaskos C, Rigopoulou E, Gabeta S, Papamichalis P, Gatselis N, et al. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clin Immunol 2006;119:203–12.PubMedCrossRef
13.
Vlachoyiannopoulos PG, Petrovas C, Tektonidou M, Krilis SA, Moutsopoulos HM. Antibodies to β2glycoprotein I: urea resistance, binding specificity and association with thrombosis. J Clin Immunol 1998;18:308–91.CrossRef
14.
Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-β2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004;63:1478–82.PubMedCrossRef
15.
Samarkos M, Davies KA, Gordon C, Loizou S. Clinical significance of IgA anticardiolipin and anti-beta2-GPI antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 2006;25:199–204.PubMedCrossRef
16.
Iverson GM, von Muhlen CA, Staub HL, Lassen AJ, Binder W, Norman GL. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun 2006;27:266–71.PubMedCrossRef
17.
Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999;117:574–9.PubMedCrossRef
18.
Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinosa LR. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999;318:55–60.PubMedCrossRef
19.
Pahor A, Hojs R, Holc I, Ambrozic A, Cucnik S, Kveder T, et al. Antiphospholipid antibodies as a possible risk factor for atherosclerosis in patients with rheumatoid arthritis. Immunobiology 2006;211:689–94.PubMedCrossRef
20.
Straub HL, Frank M, Ranzolin A, Norman GL, Iverson GM, vonMuhlen CA. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev 2006;6:104–6.CrossRef
21.
Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001;185:748–53.PubMedCrossRef
22.
Carmo-Pereira S, Bertolaccini ML, Escudero-Contreras A, Khamashta MA, Hughes GR. Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003;62:540–3.PubMedCrossRef
23.
Papamichalis PA, Zachou K, Koukoulis GK, Veloni A, Karacosta EG, Kypri L, et al. The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis 2007;4:3.PubMedCrossRef
24.
Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International autoimmune hepatitis group: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929–38.PubMedCrossRef
25.
Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005;54:528–32.PubMedCrossRef
26.
Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, et al. Anti-mitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary bilary cirrhosis. Liver Int 2007;27:1226–31.PubMed
27.
Rigopoulou EI, Bogdanos DP, Liaskos C, Koutsoumpas A, Baum H, Vergani D, et al. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta 2007;380:118–21.PubMedCrossRef
28.
29.
Kyriakou DS, Alexandrakis MG, Zachou K, Passam F, Stathakis N, Dalekos GN. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol 2003;39:679–85.PubMedCrossRef
30.
Tsikrikoni A, Kyriakou DS, Rigopoulou EI, Alexandrakis MG, Zachou K, Passam F, et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol 2005;42:393–9.PubMedCrossRef
31.
Zachou K, Rigopoulou EI, Tsikrikoni A, Alexandrakis MG, Passam F, Kyriakou DS, et al. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J Autoimmun 2005;25:283–8.PubMedCrossRef
32.
Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000;32:182–7.PubMedCrossRef
33.
Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 2005;357:17–33.PubMedCrossRef
34.
Zachou K, Rigopoulou EI, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical diagnosis and to study pathogenesis of the disease. J Autoimmune Dis 2004;1:2.PubMedCrossRef
35.
Czaja AJ. Behaviour and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30:394–401.PubMedCrossRef
36.
Oertelt S, Rieger R, Selmi C, Invernizzi P, Ansari AA, Coppel RL, et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007;45:659–65.PubMedCrossRef
37.
Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006;43:1135–44.PubMedCrossRef
38.
Tanaka A, Nezu S, Uegaki S, Mikami M, Okuyama S, Kawamura N, et al. The clinical significance of IgA antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis. Ann N Y Acad Sci 2007;1107:259–70.PubMedCrossRef
39.
Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998;7:3–6.PubMedCrossRef
40.
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New Engl J Med 2003;349:1526–33.PubMedCrossRef
Metadata
Title
IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases
Authors
Stella Gabeta
Gary L. Norman
Nikolaos Gatselis
Christos Liaskos
Panagiotis A. Papamichalis
Athanasios Garagounis
Kalliopi Zachou
Eirini I. Rigopoulou
George N. Dalekos
Publication date
01-09-2008
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 5/2008
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-008-9211-6

Other articles of this Issue 5/2008

Journal of Clinical Immunology 5/2008 Go to the issue

OriginalPaper

Decreased DNA Methyltransferase 3A and 3B mRNA Expression in Peripheral Blood Mononuclear Cells and Increased Plasma SAH Concentration in Adult Patients with Idiopathic Thrombocytopenic Purpura

OriginalPaper

IkBα Promoter Polymorphisms in Patients with Primary Sjögren’s Syndrome

OriginalPaper

Increased Granulysin Expression in Peripheral Blood Cells of Patients with Primary Biliary Cirrhosis and Its Clinical Implications

OriginalPaper

15-Deoxy-Δ12,14-Prostaglandin J2 and Curcumin Modulate the Expression of Toll-like Receptors 4 and 9 in Autoimmune T Lymphocyte

OriginalPaper

Expression of Cytokine mRNA in Lymphocytes of Malnourished Children

OriginalPaper

Histamine Release and Inflammatory Cell Infiltration in Airway Mucosa in Methylene Diphenyl Diisocyanate (MDI)-Induced Occupational Asthma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits